Ms. Denise Faltischek reports

TILRAY MEDICAL ANNOUNCES POSITIVE RESULTS FROM STUDY ON ORAL CANNABIS EXTRACT FOR CHEMOTHERAPY-INDUCED EMESIS

Tilray Medical, a division of Tilray Brands Inc. and a global leader in medical cannabis empowering the therapeutic alliance between patients and health care practitioners to make informed individualized health decisions, has released the final results of a new scientific study its team has supported titled, "Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)."

This randomized, placebo-controlled trial aimed to test the effectiveness of an oral cannabis extract in adults suffering from CINV despite standard anti-nausea treatments. Participants received capsules containing 2.5 milligrams of THC (tetrahydrocannabinol) and 2.5 milligrams of CBD (cannabidiol) or a placebo, taken three times daily for six days.

From 2016 to 2022, 147 participants were recruited. The study found that the cannabis extract significantly improved the rate of complete response -- meaning no vomiting or use of additional medications -- from 8 per cent with placebo to 24 per cent with THC and CBD. Other benefits included reduced nausea and fewer daily vomits. However, some side effects were noted, such as sedation (18 per cent versus 7 per cent), dizziness (10 per cent versus 0 per cent) and transient anxiety (4 per cent versus 1 per cent).

Denise Faltischek, chief strategy officer and head of international at Tilray Brands, said: "These findings are encouraging for cancer patients undergoing chemotherapy. This study is a crucial step in improving patient care and quality of life." She continued: "Our involvement in this study underscores our commitment to advancing medical research. The positive outcomes highlight the potential of cannabinoids for managing CINV."

Tilray Medical continues to transform lives by providing access to medical cannabis. Tilray is a leading provider of EU-GMP-certified (European Union good manufacturing practice) medical cannabis products in over 20 countries. The company has supported medical trials globally, studying cannabis for various conditions, including pediatric epilepsy, cancer-induced nausea and PTSD (posttraumatic stress disorder).

About Tilray Medical

Tilray Medical is dedicated to transforming lives and fostering dignity for patients in need through safe and reliable access to a global portfolio of medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and Navcora. Tilray grew from being one of the first companies to become an approved licensed producer of medical cannabis in Canada to building the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis to patients, physicians, hospitals, pharmacies, researchers and governments in 20 countries and across five continents.

About Tilray Brands Inc.

Tilray Brands is a leading global lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia and Latin America that is leading as a transformative force at the nexus of cannabis, beverage, wellness and entertainment, elevating lives through moments of connection. Tilray's mission is to be a leading premium lifestyle company with a house of brands and innovative products that inspire joy and create memorable experiences. Tilray's unprecedented platform supports over 40 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods and craft beverages.

We seek Safe Harbor.